1 week Ago By ABMN Staff
Arrowstreet Capital Limited Partnership acquired a new stake in Illumina, Inc. ( NASDAQ:ILMN – Free Report ) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 67,519 shares of the life sciences company’s stock, valued at approximately $9,023,000.
Several other hedge funds also recently bought and sold shares of the stock. Allstate Corp acquired a new position in shares of Illumina in the 4th quarter worth approximately $631,000. DnB Asset Management AS lifted its stake in Illumina by 120.
0% during the fourth quarter. DnB Asset Management AS now owns 59,376 shares of the life sciences company’s stock worth $7,934,000 after purchasing an additional 32,385 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in Illumina by 245.
7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock worth $158,011,000 after purchasing an additional 840,423 shares in the last quarter. AKO Capital LLP purchased a new position in shares of Illumina during the fourth quarter worth $66,185,000.
Finally, Norges Bank acquired a new stake in shares of Illumina in the fourth quarter valued at $228,714,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Illumina Stock Down 3.0 % Illumina stock opened at $74.16 on Monday.
The stock has a 50 day moving average of $96.82 and a two-hundred day moving average of $125.02.
Illumina, Inc. has a twelve month low of $70.64 and a twelve month high of $156.
66. The stock has a market capitalization of $11.75 billion, a price-to-earnings ratio of -9.
66, a PEG ratio of 1.60 and a beta of 1.38.
The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.
63. Analyst Upgrades and Downgrades Several equities analysts have commented on the stock. Canaccord Genuity Group decreased their price target on shares of Illumina from $135.
00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th.
TD Cowen cut Illumina from a “buy” rating to a “hold” rating and decreased their price objective for the company from $177.00 to $140.00 in a research note on Friday, February 7th.
Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.
00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Finally, Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.
00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $140.
90. Read Our Latest Stock Analysis on Illumina Illumina Profile ( Free Report ) Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments.
The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Featured Stories Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc.
( NASDAQ:ILMN – Free Report ). Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter .
.
